Funds › Affinity Asset Advisors, LLC
Affinity Asset Advisors, LLC
13F for Q3 2026, filed Nov 13, 2026. 106 positions worth $2.5B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q3 2026
filed Nov 13, 2026
Reported value
$2.5B
+$245.1M (11.1%) vs Q2 2026
Positions
106
101 in Q2 2026
Top 10 share
29.9%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Affinity Asset Advisors, LLC in the latest 13F quarter?
Using 13F.ai, how has Affinity Asset Advisors, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Affinity Asset Advisors, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | ROIV Roivant Sciences Ltd. | 3.20M | $117.0M | 4.8% | -14.7% | 13F ↗ |
| 2 | SYRE Spyre Therapeutics, Inc. | 1.28M | $113.9M | 4.6% | Unchanged | 13F ↗ |
| 3 | ERAS Erasca, Inc. | 5.59M | $82.0M | 3.3% | +6.5% | 13F ↗ |
| 4 | TRAX First Tracks Biotherapeutics, Inc. · Ord Shs *A* | 2.08M | $73.7M | 3.0% | +2.4% | 13F ↗ |
| 5 | XENE Xenon Pharmaceuticals Inc. | 1.90M | $70.7M | 2.9% | +19.1% | 13F ↗ |
| 6 | INSM Insmed Incorporated · Com Par $.01 | 564,251 | $64.4M | 2.6% | -13.2% | 13F ↗ |
| 7 | ALKS Alkermes plc | 1.56M | $63.4M | 2.6% | +39.1% | 13F ↗ |
| 8 | ORKA Oruka Therapeutics, Inc. | 600,000 | $50.0M | 2.0% | +1.7% | 13F ↗ |
| 9 | AVTX Avalo Therapeutics, Inc. | 3.24M | $49.7M | 2.0% | +11.9% | 13F ↗ |
| 10 | CYTK Cytokinetics, Incorporated | 750,000 | $49.4M | 2.0% | +36.4% | 13F ↗ |
| 11 | RVMD Revolution Medicines, Inc. | 225,000 | $46.2M | 1.9% | -10.0% | 13F ↗ |
| 12 | PRAX Praxis Precision Medicines, Inc. | 155,000 | $45.1M | 1.8% | -16.2% | 13F ↗ |
| 13 | BLTE Belite Bio, Inc | 242,088 | $41.1M | 1.7% | +46.7% | 13F ↗ |
| 14 | CLDX Celldex Therapeutics, Inc. | 1.16M | $37.6M | 1.5% | +65.8% | 13F ↗ |
| 15 | ABVX Abivax SA · ADR | 330,000 | $32.7M | 1.3% | Unchanged | 13F ↗ |
| 16 | DNTH Dianthus Therapeutics, Inc. | 350,000 | $30.8M | 1.3% | -12.5% | 13F ↗ |
| 17 | ODTX Odyssey Therapeutics, Inc. | 1.26M | $28.0M | 1.1% | +64.4% | 13F ↗ |
| 18 | ARWR Arrowhead Pharmaceuticals, Inc. | 425,000 | $27.8M | 1.1% | +183% | 13F ↗ |
| 19 | TRVI Trevi Therapeutics, Inc. | 1.80M | $25.8M | 1.0% | Unchanged | 13F ↗ |
| 20 | OVID Ovid Therapeutics Inc. | 10.14M | $25.3M | 1.0% | Unchanged | 13F ↗ |
| 21 | SGMT Sagimet Biosciences Inc. | 2.53M | $25.0M | 1.0% | +1.2% | 13F ↗ |
| 22 | LXEO Lexeo Therapeutics, Inc. | 7.25M | $24.5M | 1.0% | +24.8% | 13F ↗ |
| 23 | PTGX Protagonist Therapeutics, Inc. | 172,125 | $24.3M | 1.0% | Unchanged | 13F ↗ |
| 24 | NRIX Nurix Therapeutics, Inc. | 967,620 | $22.9M | 0.9% | Unchanged | 13F ↗ |
| 25 | VOGX Vogenx Inc | 915,000 | $20.9M | 0.8% | New | 13F ↗ |
| 26 | MLYS Mineralys Therapeutics, Inc. | 750,000 | $18.8M | 0.8% | Unchanged | 13F ↗ |
| 27 | TYRA Tyra Biosciences, Inc. | 850,000 | $18.6M | 0.8% | +325% | 13F ↗ |
| 28 | STRO Sutro Biopharma, Inc. | 1.15M | $18.6M | 0.8% | -1.7% | 13F ↗ |
| 29 | TVTX Travere Therapeutics, Inc. | 300,000 | $17.7M | 0.7% | Unchanged | 13F ↗ |
| 30 | ANRO Alto Neuroscience, Inc. | 643,343 | $16.4M | 0.7% | -24.3% | 13F ↗ |
| 31 | ARVN Arvinas, Inc. | 2.05M | $15.9M | 0.6% | New | 13F ↗ |
| 32 | EPRX Eupraxia Pharmaceuticals Inc. · Com 298736 Al 3 Euronet Worldwide Inc Note 0.750% 3/1 | 1.72M | $15.6M | 0.6% | +4.0% | 13F ↗ |
| 33 | RLAY Relay Therapeutics, Inc. | 850,000 | $15.3M | 0.6% | -19.0% | 13F ↗ |
| 34 | MDGL Madrigal Pharmaceuticals, Inc. | 30,000 | $15.1M | 0.6% | -25.0% | 13F ↗ |
| 35 | CGEM Cullinan Therapeutics, Inc. | 875,760 | $13.4M | 0.5% | Unchanged | 13F ↗ |
| 36 | SVRA Savara, Inc. | 2.51M | $13.0M | 0.5% | Unchanged | 13F ↗ |
| 37 | COAG Hemab Therapeutics Holdings, Inc. | 420,000 | $13.0M | 0.5% | +204% | 13F ↗ |
| 38 | CLYM Climb Bio, Inc. | 972,000 | $11.1M | 0.5% | Unchanged | 13F ↗ |
| 39 | IBRX ImmunityBio, Inc. | 1.18M | $11.1M | 0.5% | New | 13F ↗ |
| 40 | BEAM Beam Therapeutics Inc. | 450,000 | $11.0M | 0.4% | New | 13F ↗ |
| 41 | CATX Perspective Therapeutics, Inc. | 3.99M | $11.0M | 0.4% | -5.4% | 13F ↗ |
| 42 | JBIO Jade Biosciences, Inc. | 760,350 | $10.7M | 0.4% | -9.5% | 13F ↗ |
| 43 | PRLD Prelude Therapeutics Incorporated | 2.60M | $10.2M | 0.4% | New | 13F ↗ |
| 44 | CRSP CRISPR Therapeutics AG · Namen Akt | 175,000 | $9.7M | 0.4% | +75.0% | 13F ↗ |
| 45 | MANE Veradermics, Incorporated | 79,400 | $9.6M | 0.4% | -20.6% | 13F ↗ |
| 46 | ESTA Establishment Labs Holdings Inc. | 149,779 | $9.6M | 0.4% | +1.2% | 13F ↗ |
| 47 | AMLX Amylyx Pharmaceuticals, Inc. | 300,000 | $8.7M | 0.4% | +203% | 13F ↗ |
| 48 | KRSA Korsana Biosciences, Inc. | 263,106 | $8.4M | 0.3% | New | 13F ↗ |
| 49 | PRQR ProQR Therapeutics N.V. · Shs Euro | 4.97M | $8.3M | 0.3% | -10.4% | 13F ↗ |
| 50 | VERA Vera Therapeutics, Inc. | 250,000 | $8.1M | 0.3% | Unchanged | 13F ↗ |
Showing the top 50 of 106 positions. Premium lists every position, plus puts and calls.
Changes since Q2 2026
25 new, 27 added to, 26 trimmed, 20 exited, 28 unchanged. By estimated dollars.
New positions (25)
| VOGX Vogenx Inc | 915,000 | New | $20.9M |
| ARVN Arvinas, Inc. | 2.05M | New | $15.9M |
| IBRX ImmunityBio, Inc. | 1.18M | New | $11.1M |
| BEAM Beam Therapeutics Inc. | 450,000 | New | $11.0M |
| PRLD Prelude Therapeutics Incorporated | 2.60M | New | $10.2M |
| KRSA Korsana Biosciences, Inc. | 263,106 | New | $8.4M |
| DMRA Damora Therapeutics, Inc. · Comm Stk | 375,000 | New | $8.0M |
| AKTS Aktis Oncology, Inc. | 350,000 | New | $6.8M |
| SLN Silence Therapeutics Plc · ADR | 450,000 | New | $4.9M |
| IRD Opus Genetics, Inc. | 900,000 | New | $4.4M |
Added to (27)
| ARWR Arrowhead Pharmaceuticals, Inc. | 425,000 | +183% | $18.0M |
| ALKS Alkermes plc | 1.56M | +39.1% | $17.8M |
| CLDX Celldex Therapeutics, Inc. | 1.16M | +65.8% | $14.9M |
| TYRA Tyra Biosciences, Inc. | 850,000 | +325% | $14.2M |
| CYTK Cytokinetics, Incorporated | 750,000 | +36.4% | $13.2M |
| BLTE Belite Bio, Inc | 242,088 | +46.7% | $13.1M |
| XENE Xenon Pharmaceuticals Inc. | 1.90M | +19.1% | $11.4M |
| ODTX Odyssey Therapeutics, Inc. | 1.26M | +64.4% | $11.0M |
| COAG Hemab Therapeutics Holdings, Inc. | 420,000 | +204% | $8.7M |
| AMLX Amylyx Pharmaceuticals, Inc. | 300,000 | +203% | $5.8M |
Trimmed (26)
| ANAB AnaptysBio, Inc. | 66,464 | -92.0% | -$38.2M |
| ROIV Roivant Sciences Ltd. | 3.20M | -14.7% | -$20.1M |
| ELVN Enliven Therapeutics, Inc. | 148,000 | -70.4% | -$16.1M |
| INSM Insmed Incorporated · Com Par $.01 | 564,251 | -13.2% | -$9.8M |
| PRAX Praxis Precision Medicines, Inc. | 155,000 | -16.2% | -$8.7M |
| IDYA IDEAYA Biosciences, Inc. | 200,000 | -50.0% | -$7.7M |
| HLXC Helix Acquisition Corp. III | 625,000 | -50.0% | -$6.6M |
| ANRO Alto Neuroscience, Inc. | 643,343 | -24.3% | -$5.3M |
| RVMD Revolution Medicines, Inc. | 225,000 | -10.0% | -$5.1M |
| MDGL Madrigal Pharmaceuticals, Inc. | 30,000 | -25.0% | -$5.0M |
Exited (20)
| Apogee Therapeutics Inc | 987,000 | Exited | -$131.0M |
| Nuvalent Inc | 275,000 | Exited | -$34.0M |
| Forte Biosciences Inc | 1.15M | Exited | -$24.3M |
| COGT Cogent Biosciences, Inc. | 450,000 | Exited | -$17.4M |
| Teva Pharmaceutical Industries Ltd ADR | 374,000 | Exited | -$12.7M |
| Damora Therapeutics Inc | 425,000 | Exited | -$11.1M |
| QURE uniQure N.V. | 175,000 | Exited | -$8.1M |
| ASND Ascendis Pharma A/S | 30,000 | Exited | -$8.0M |
| ASMB Assembly Biosciences, Inc. | 190,000 | Exited | -$5.2M |
| BHVN Biohaven Ltd. | 250,000 | Exited | -$3.7M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | 13F-HR | 121 | $2.5B | Current | SEC ↗ |
| Q2 2026 | Aug 13, 2026 | 13F-HR | 113 | $2.2B | Current | SEC ↗ |
| Q1 2026 | May 14, 2026 | 13F-HR | 105 | $1.9B | Current | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | 13F-HR | 95 | $1.8B | Current | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | 13F-HR | 96 | $1.1B | Current | SEC ↗ |
| Q2 2025 | Aug 13, 2025 | 13F-HR | 91 | $732.2M | Current | SEC ↗ |
| Q1 2025 | May 14, 2025 | 13F-HR | 98 | $1.0B | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer